07/12/2017 11:30:16

Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference

LEXINGTON, Mass. and LONDON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in a fireside chat at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Thursday, Dec. 14, 2017 at 9:00 a.m. ET in New York City.

To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for 60 days following the conference.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar's lead product candidate, NSR-REP1, is being developed as a treatment for patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments and affects approximately one in every 50,000 people. Positive results from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in 2014 and in The New England Journal of Medicine in 2016. Nightstar plans to commence a Phase 3 registrational trial of NSR-REP1 for choroideremia at sites in the United States, Europe and Canada in the first half of 2018. Nightstar's second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease that affects approximately one in every 40,000 people.

For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements about our plans to develop and commercialize our product candidates, our planned clinical trials for NSR-REP1 and NSR-RPGR, the clinical utility of our product candidates, the prevalence of patient populations for our targeted indications, and the utility of prior preclinical and clinical data in determining future clinical results . These forward-looking statements are based on management's current expectations of future events and are subject to a number of involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risks and uncertainties set forth in the "Risk Factors" section of our prospectus filed pursuant to Rule 424(b)(4) under the U.S. Securities Act of 1933, as amended, on September 28, 2017, and subsequent reports that we file with the U.S. Securities and Exchange Commission. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Contact:

Senthil Sundaram, Chief Financial Officer

investors@nightstartx.com 

Alicia Davis, THRUST IR

910-620-3302

alicia@thrustir.com 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nightstar Therapeutics via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Oct
DANSKE
Stop dog for helvede dine sindsyge indlæg. Det er brugere som dig der fuldkommen smadrer det her for..
31
16 Oct
DANSKE
Jeg tror aldrig jeg har oplevet en person, der var så bitter som du er. Du bruger en ufattelig masse..
28
11 Oct
OMXC25
... og det betyder som regel, at det er sidste ben i nedturen, før en pause, eller en positiv modrea..
24
13 Oct
PNDORA
Carnegie's seneste analyse gav lidt medvind til pandora, men det var slet ikke meningen, idet alle j..
21
12 Oct
DANSKE
Ole Andersen havde ansat 5 kanibaler til at ryde op efter hvidvasskandalen. I har nu fast arbejde, t..
21
14 Oct
DANSKE
En korruptionsbekæmper skudt i Moskva, er nu også blevet Danske Banks skyld, hvor ussel kan denne p..
18
12 Oct
DANSKE
Der er noget ejendommeligt ved danmarkshistoriens formentlig største pengeinstitutskandale: Formentl..
15
16 Oct
VELO
HVAD SIGER VELOXIS og HVAD GØR MARKEDET...    Lad os starte med hvad sagde Craig Collard ved regnska..
14
15 Oct
VELO
Hej Veloxis er i dag nævnt som en af de 3 aktier man bør fokusere på. https://play.borsen.dk/klip/5b..
14
13 Oct
CHEMM
@Tommy, Du stiller et meget relevant spørgsmål, men først vil jeg korrigere lidt på dit P/E. Som inv..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
2
Glance Reports Third Quarter 2018 Results
3
Axiom Real-Time Metrics Exhibiting at OCT Pacific Northwest in Vancouver
4
Ctrip and KLM Sign Strategic Partnership Agreement
5
Atos and Siemens team up to enable enterprises to deploy IoT applications on private Cloud

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 October 2018 00:30:14
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB1 - 2018-10-18 01:30:14 - 2018-10-18 00:30:14 - 1000 - Website: OKAY